Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atrial natriuretic factor prohormone 31-67 - Madeleine Pharmaceuticals

Next Previous
Drug Profile

Atrial natriuretic factor prohormone 31-67 - Madeleine Pharmaceuticals

Alternative Names: MAD-001; MP-3167; Pro ANP 31-67; ProANF 31-67; Vastiras; Vessel dilator - Madeleine; VSDL

Latest Information Update: 17 Aug 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Madeleine Pharmaceuticals
  • Developer Madeleine Pharmaceuticals; Medtronic
  • Class Heart failure therapies; Natriuretic peptides; Peptides
  • Mechanism of Action Atrial natriuretic factor receptor agonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 30 Jul 2018 Madeleine terminates the phase II CONTINUUM-HF trial for Heart failure in Australia (IV, infusion; SC, infusion) (ACTRN12613001060730)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Australia (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Australia (SC, Implant)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top